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Abstract
Background: Inherited BRCA1 and BRCA2 (BRCA1/2) mutations confer elevated breast cancer risk.
Knowledge of factors that can improve breast cancer risk assessment in BRCA1/2 mutation carriers may
improve personalized cancer prevention strategies.
Methods: A cohort of 5,546 BRCA1 and 2,865 BRCA2 mutation carriers was used to evaluate risk of breast
cancer associated with BARD1 Cys557Ser. In a second nonindependent cohort of 1,537 of BRCA1 and 839
BRCA2 mutation carriers, BARD1 haplotypes were also evaluated.
Results: The BARD1 Cys557Ser variant was not significantly associated with risk of breast cancer from
single SNP analysis, with a pooled effect estimate of 0.90 (95% CI: 0.71–1.15) in BRCA1 carriers and 0.87 (95%
CI: 0.59–1.29) in BRCA2 carriers. Further analysis of haplotypes at BARD1 also revealed no evidence that
additional common genetic variation not captured by Cys557Ser was associated with breast cancer risk.
Conclusion: Evidence to date does not support a role for BARD1 variation, including the Cy557Ser variant,
as a modifier of risk in BRCA1/2 mutation carriers.
Impact: Interactors of BRCA1/2 have been implicated as modifiers of BRCA1/2-associated cancer
risk. Our finding that BARD1 does not contribute to this risk modification may focus research on
other genes that do modify BRCA1/2-associated cancer risk. Cancer Epidemiol Biomarkers Prev; 20(5);
1032–38. 2011 AACR.
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Introduction
There is substantial interindividual variability in age at
cancer diagnosis in BRCA1 and BRCA2mutation carriers,
which persists even among relatives that carry the same
BRCA1 and BRCA2 mutation (1). Variation in genes that
interact with BRCA1 and BRCA2 in the recognition and
repair of DNA damage are strong candidates for study as
genetic modifiers of BRCA1 and BRCA2 cancer risk. The
BRCA1–BARD1 heterodimer is known to be important for
BRCA1 function, with interaction mediated through the
ring finger domains of the 2 proteins (2). In addition,
although there is no evidence for a direct interaction
between BARD1 and BRCA2, they do operate in the
same DNA repair processes, exemplified by the fact that
the BRCA2 partner RAD51, BARD1, and BRCA1 all
relocate to proliferating cell nuclear antigen structures
after irradiation (3).
The BARD1 Cys557Ser SNP (rs28997576) was first
reported as a germ line alteration in a sporadic breast/
uterine tumor (4). This variant lies between the ankyrin
repeats and BRCT domains of BARD1, and the ectopically
expressed Cys557 protein has growth suppression and
proapoptotic effects relative to 557Ser (5). This SNP
(minor allele frequency in Europeans: 0.025) has been
reported to be associated with both breast cancer in the
general population and familial breast cancer, but results
have not shown consistent across all studies (6–12). Sta-
cey and colleagues (6) initially reported that the Cys557-
Ser variant was associated with increased breast cancer
risk in 756 Icelandic mutation carriers who carry BRCA2
999del5 founder mutation [OR ¼ 3.1; 95% CI: 1.2–8.4].
However, subsequent studies reported no elevated risk in
228 Nordic BRCA1 and BRCA2 carriers (OR¼ 0.8, 95%CI:
0.3–2.0; ref. 8), or in 1,207 Polish BRCA1mutation carriers
(OR ¼ 0.9, 95% CI: 0.4–2.2; ref. 10). There have been no
previous haplotype-based studies assessing the role of
BARD1 variation in breast cancer risk in BRCA1 and
BRCA2 carriers specifically.
To resolve whether BARD1 is a modifier of BRCA1 and
BRCA2-associated breast cancer risk, we undertook a
large study to comprehensively assess the association
of BARD1 Cys557Ser as well as haplotypic variation with
cancer risk in BRCA1 and BRCA2 carriers.
Materials and Methods
Study sample
The design for this study has been described in detail
previously (13). Briefly, eligible participants included
adult women with documented disease-associated inher-
ited mutations in BRCA1 or BRCA2. Mutations were
included in the analysis if they were pathogenic accord-
ing to generally recognized criteria (14, 15). Two over-
lapping cohorts of women with disease-associated
BRCA1 and BRCA2 mutations were identitied (Table 1).
First, a cohort of 5,546 BRCA1 and 2,865 BRCA2mutation
carriers from themulticenter CIMBA consortium (13)was
used to evaluate risk of breast cancer associated with
BARD1 Cys557Ser. Second, a cohort of 1,537 of BRCA1
and 839 BRCA2 mutation carriers participating in the
MAGIC consortium was used to further explore the
relationship between BARD1 haplotypes and breast can-
cer risk. Recruitment and genetic studies were approved
by relevant ethics committees at all sites, and informed
consent was obtained from each participant.
Laboratory methods
For analysis of the BARD1 Cys557Ser SNP, existing
genotype data from BRCA1 and BRCA2mutation carriers
was requested from members of the CIMBA consortium.
The primary methods used for genotyping were Seque-
nom iPlex (EMBRACE, -HEBON, kConFab, SWE-BRCA,
PISA, Penn, Austria, Mayo, FCCC, GEMO, Georgetown,
HEBCS) and by Taqman assays (OUH, Baylor, Beth
Israel, City of Hope, Creighton, Dana Farber, NorthShore,
IHCC, UCLA, University of Chicago, University of Texas
Health Science Center, University of Utah, and Women’s
College Hospital; ref. 16) Genotypes for the INHERIT
samples were typed by direct sequencing using an ABI
Prism 3730xl DNA Analyser automated sequencer, with
version 3.1 of the Big Dye fluorescent method according
to the manufacturer’s instructions (Applied Biosystems).
Sequence data were analyzed using the Staden preGap4
and Gap4 programs. Samples from IHCC were typed by
PCR-RFLP (10). SNP quality control measures included
more than 95% success rate, Hardy–Weinberg Equili-
brium P > 0.005. In addition, concordance of more than
98% for duplicate samples was required for studies that
had included 2% duplicated samples for quality control
purposes (all studies undergoing Sequenom iplex for
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BARD1 Cys557Ser, and all samples included in the hap-
lotype substudy).
For studies of BARD1 haplotypic variation, 11 haplo-
type tag SNPs were identified and assayed at the Uni-
versity of Pennsylvania as previously described (16). The
rs IDs were as follows: rs6712055, rs16852689, rs280621,
rs13021937, rs13423596, rs10190829, rs6751923, rs4234006,
rs28997576, rs3768708, rs1374230.
Statistical methods
To assess the relationship between BARD1 SNPs and
breast cancer risk, proportional hazards models were
used as previously described (16, 17). Briefly, participants
were followed from the time of genetic testing or study
ascertainment until the first diagnosis of breast cancer
(the primary event in this analysis) or were censored at
ovarian cancer. Participants who developed breast cancer
were censored at bilateral prophylactic mastectomy if it
occurred more than a year prior to the cancer diagnosis.
This is to avoid censoring at bilateral mastectomies at
which occult tumorswere detected, but ages are rounded.
The remaining participants were censored at the age at
last observation. To address the problem of nonrandom
sampling of mutation carriers with respect to the disease
phenotype, analyses used the weighted Cox regression
approach (17), where affected and unaffected individuals
were differentially weighted such that observed breast
cancer incidence rates in the study sample are consistent
with established breast cancer risk estimates for BRCA1
and BRCA2mutation carriers (18). Analyses assessing the
association of the BARD1 Cys557Ser SNP combined het-
erozygote and homozygote variant carriers under a
dominant model because of the rare frequency of this
variant. Analyses were assessed separately for BRCA1
and BRCA2 mutation carriers, adjusted for Study group,
ethnicity (non-Jewish Caucasian, Jewish or other), and
Table 1. Sample description and Cys557Ser association
Center Data in Cys557Ser analysis Data in haplotype analysis
BRCA1 BRCA2 BRCA1 BRCA2
Austria 285 122 196 60
Baylor 14 1
Beth Israel 7 12
City of Hope 68 42
Creighton 180 41
Dana Farber 90 38
EMBRACE 827 638
NorthShore 31 20
Fox Chase 85 57 40 26
Georgetown 33 16 60 29
GEMO 1,140 559
HEBON 777 294
HEBCS 102 104
IHCC 397
INHERIT 73 82
KConFab 506 400 379 302
MAGICa 583 300
Mayo 218 118 58 31
OUH 33 13
Penn 202 98
Pisa (PBCS) 73 41
Swe-BRCA 414 121
UCLA 32 14
Univ of Chicago 27 11
UT Southwestern 28 19
Utah 99 78
Women's College 26 17
Total 5,546 2,865 1,537 839
Cys557Ser association 0.90 (0.71–1.15) 0.87 (0.59–1.29) ND ND
Abbreviation: ND, not done.
aIndicates MAGIC data included in single SNP analysis only.
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year of birth cohort (decade of birth, categorized as <1940,
1940–1949, 1950–1959, 1960–1969, 1970–1989). There were
3,047 breast cancer events of 5,546 total for BRCA1 (55%)
and 1,578 breast cancer events of 2,865 total for BRCA2
(55%) for the Cys557Ser censored analysis datasets. The
remainders were censored for analysis. Secondary ana-
lyses adjusted for prophylactic oophorectomy, or
assessed risk for the subset of carriers with mutations
determined to result in unstable transcripts/proteins
(class 1 loss of function mutations). R version 2.7.0 was
used for single SNP statistical analyses.
To investigate haplotype effects, the Estimation-max-
imization algorithm (19, 20) was used to estimate haplo-
type frequencies as implemented in R version 2.1.1
subroutine haplo.em (21) as previously described (16).
In this analysis, we included 607 breast cancer cases and
863 censored observations for BRCA1, and 813 breast
cancer cases and 423 controls for BRCA2.
Results and Discussion
The frequency of the Cys557Ser SNP in the combined
dataset (Table 1) was similar to published reports, with
4.4% of individuals carrying at least 1 rare allele (4.5% in
BRCA1 carriers, 4.2% in BRCA2 carriers). There were no
significant associations of Cys557Ser and breast cancer
risk for carriers of BRCA1mutations (HR¼ 0.90, 95% CI:
0.71–1.15) or BRCA2 mutations (HR ¼ 0.87, 95% CI:
0.59–1.29). There was no evidence for heterogeneity
by center for either BRCA1 or BRCA2 analyses (P >
0.5). There was also no evidence for association with
additional adjustment for prophylactic oophorectomy,
or when analyses were restricted to Class 1 mutations.
For example, the HR for the subset of 3,882 individuals
with BRCA1 Class 1 mutations was 0.84 (0.62–1.15), and
for the 2,668 individuals with BRCA2 class 1 mutations
was 0.96 (0.64–1.45).
For the haplotype analysis (Table 2), we also observed
no overall effect of variation at BARD1 in either BRCA1
false discovery rate (FDR-corrected value of P ¼ 0.152) or
BRCA2 (FDR-corrected value of P ¼ 0.134). No single
BARD1 haplotype was significantly associated with
breast cancer risk. Cys557Ser is represented by SNP 16
in Table 2 (BRCA1 haplotype 8 and BRCA2 haplotype 10).
Since this variant was relatively rare (approximately 2%
in both BRCA1 and BRCA2 carriers), estimates of its effect
were not made in our primary analysis. When we fit a
model that allowed the estimation of effects for haplo-
types with at least 1% frequency in controls, no single
haplotype was significantly associated with risk. The
haplotype that contained the 557Ser allele was also not
significantly associated with risk in either BRCA1 (HR ¼
0.91, 95% CI: 0.45–1.85) or BRCA2 (HR ¼ 0.69, 95% CI:
0.28–1.72). Indeed, neither of these estimates was asso-
ciated with increased risk of breast cancer as previously
reported.
The data presented here do not provide evidence that
neither the BARD1 Cys557Ser SNP nor additional hap-
lotypic variability not captured by Cys557Ser is asso-
ciated with breast cancer risk in BRCA1 and BRCA2
mutation carriers. Our sample size had more than 99%
power to detect the effect size reported by Stacey and
colleagues (6) of OR ¼ 3.1. The study had more than 80%
power to detect risk ratios of 0.89 (or 1.13) for BRCA1
carriers and 0.86 (or 1.17) for BRCA2 carriers. The upper
95% confidence limits on the rate ratio in our analysis
exclude any substantial risk.
Conclusion
Our study found no evidence to support substantial
associations of BARD1 variation with increased breast
cancer risk in BRCA1 and BRCA2 carriers.
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